AC Immune SA (ACIU) News
Track canonical SquawkNews coverage tagged to ACIU, AC Immune SA. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
ACIU reports positive preliminary Phase 1 data for Aci-19764
ACIU Ac immune says its NLRP3 inhibitor Aci-19764 shows positive preliminary Phase 1 findings, including reported safety/tolerability and confirmed CSF penetration, with full Phase 1/1B results expected in H1 2027.
EQUITY | Aug 20, 2026, 11:01 AM UTC
L
AC Immune reports positive preliminary Phase 1 data for ACI-19764
AC Immune says preliminary Phase 1 data for its NLRP3 inhibitor ACI-19764 are positive, with no further details on the findings supplied in the alert.
EQUITY | Aug 20, 2026, 11:00 AM UTC